Leading provider of global mobile connectivity, iPass, Inc. (NASDAQ:IPAS), announces that Bezeq, Israel’s leading telecoms group, is using iPass technology to bring global Wi-Fi to its customers. REDWOOD SHORES, CA–(Marketwired – Oct 17, 2016) – iPass Inc. ( NASDAQ : IPAS ), the leading provider of global mobile connectivity, today announced that Bezeq, Israel’s largest and leading telecoms group, has deployed and is using the iPass SmartConnect™ Software Development Kit […]Read More ˃
Shareholders of Biodel, Inc. (NASDAQ:BIOD) have received a recommendation of placing a “For” vote by leading proxy advisory firms on each of the proposals to be voted on for Biodel’s annual meeting of stockholders. DANBURY, Conn., Oct. 17, 2016 /PRNewswire/ — Biodel Inc. (BIOD) (“Biodel” or the “Company”) is pleased to announce that two leading proxy voting advisory firms, Institutional Shareholder Services, Inc. (ISS) and Glass, Lewis & Co., have […]Read More ˃
Sify Technologies, Ltd. (ADR) (NASDAQ:SIFY) Reports Their Second Quarter Revenues. How Will the Market Respond?
Leader in Managed Enterprise, Network, IT and Application services based in Chennai, India, announced its consolidated results. SANTA CLARA, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) — Sify Technologies Limited (SIFY), headquartered at Chennai, India, a leader in Managed Enterprise, Network, IT and Applications services in India with global delivery capabilities, today announced its consolidated results under International Financial Reporting Standards (IFRS) for the second quarter of fiscal year 2016-17. PERFORMANCE […]Read More ˃
Shares of IntelliPharmaCeutics International, Inc. (NASDAQ:IPCI) Take a Big Leap After Signing New Licensing Deal With Mallinckrodt
IntelliPharmaCeutics International, Inc. (NASDAQ:IPCI) has reached a new deal, entering into a license and commercial supply agreement with Mallinckrodt to market, sell, and distribute IntelliPharmaCeutics’s extended release products in the United States. Shares of IntelliPharmaCeutics International PLC (IPCI) rose on Tuesday after the company reported a new licensing deal with Mallinckrodt PLC (MNK). Specifically, the company entered into a license and commercial supply agreement with Mallinckrodt to market, sell and […]Read More ˃
Viking Therapeutics, Inc. (NASDAQ:VKTX) Doses First Patient in New Clinical Trial, How Will Investors Respond?
Clinical-stage biopharmaceutical company, Viking Therapeutics, Inc. (NASDAQ:VKTX), announces that the first patient has been dosed in the company’s Phase 2 clinical trial of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease. SAN DIEGO, Oct. 4, 2016 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the first patient has been […]Read More ˃
Stock Plummets Upon News that Ultrapetrol (Bahamas), Ltd. (NASDAQ:ULTR) Will be Delisted From Nasdaq
Ultrapetrol (Bahamas), Ltd. (NASDAQ:ULTR) revealed that they will be delisted by the Nasdaq Stock Exchange effective October 19th. NASSAU, Bahamas, Oct. 18, 2016 (GLOBE NEWSWIRE) — Ultrapetrol (Bahamas) Limited (ULTR) (“Ultrapetrol” or the “Company”), announced today that it received notice from the Nasdaq Stock Exchange (“Nasdaq”), dated October 17, 2016, indicating that the Nasdaq Hearings Panel has denied the Company’s appeal for continued listing on the Nasdaq Capital Market. The […]Read More ˃